CureVac Reported Q1 2024 Pre-Tax Loss Of €69.9M Vs. €57.4M YoY
Portfolio Pulse from Benzinga Newsdesk
CureVac reported a Q1 2024 pre-tax loss of €69.9 million, compared to a loss of €57.4 million in the same period last year.
May 23, 2024 | 11:07 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
CureVac reported a Q1 2024 pre-tax loss of €69.9 million, an increase from the €57.4 million loss in the same period last year. This indicates a worsening financial performance.
The increase in pre-tax loss from €57.4 million to €69.9 million suggests deteriorating financial health, which is likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100